Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Bevacizumab
100%
Concurrent Radiation
100%
Temozolomide
100%
Resection
100%
Pituitary Carcinoma
100%
Successful Treatment
100%
Adrenocorticotropic Hormone
40%
Aggressive pituitary Tumor
40%
Older Men
20%
Combination Therapy
20%
Tumor
20%
High Risk
20%
Radiation Therapy
20%
Visual Loss
20%
Antiangiogenic Agents
20%
Surgical Resection
20%
High-level Expression
20%
Optimal Treatment
20%
Necrosis
20%
Vascular Endothelial Growth Factor
20%
Tumor Marker
20%
No Recurrence
20%
Pituitary Adenoma
20%
Distant Metastasis
20%
Mitotic Figures
20%
Pulmonary Nodule
20%
Concurrent Chemoradiation
20%
Concurrent Chemoradiation Therapy
20%
Pituitary Neoplasms
20%
Histopathological Features
20%
Serum-based
20%
During Treatment
20%
Adjuvant Setting
20%
Medicine and Dentistry
Temozolomide
100%
Bevacizumab
100%
Pituitary Cancer
100%
Recurrent Disease
60%
Corticotropin
40%
Pituitary Tumour
40%
Morphology
20%
Combination Therapy
20%
Neoplasm
20%
Tumor Marker
20%
Chemoradiotherapy
20%
Vasculotropin
20%
Chemoradiation Therapy
20%
Necrosis
20%
Visual Impairment
20%
Pituitary Adenoma
20%
Angiogenesis Inhibitor
20%
Distant Metastasis
20%
Lung Nodule
20%
Radiation Therapy
20%
Nursing and Health Professions
Carcinoma
100%
Bevacizumab
100%
Temozolomide
100%
Recurrent Disease
60%
Corticotropin
40%
Hypophysis Tumor
40%
Chemoradiotherapy
40%
Hypophysis Adenoma
20%
Visual Impairment
20%
Combination Therapy
20%
Necrosis
20%
Distant Metastasis
20%
Vasculotropin
20%
Lung Nodule
20%
Neoplasm
20%
Tumor Marker
20%
Angiogenesis Inhibitor
20%
Radiotherapy
20%
Pharmacology, Toxicology and Pharmaceutical Science
Bevacizumab
100%
Temozolomide
100%
Carcinoma
100%
Recurrent Disease
60%
Chemoradiation Therapy
40%
Corticotropin
40%
Hypophysis Tumor
40%
Vasculotropin
20%
Visual Impairment
20%
Necrosis
20%
Distant Metastasis
20%
Lung Nodule
20%
Hypophysis Adenoma
20%
Neoplasm
20%
Combination Therapy
20%
Angiogenesis Inhibitor
20%
Tumor Marker
20%
Neuroscience
Bevacizumab
100%
Temozolomide
100%
Adrenocorticotropic Hormone
40%
Pituitary Tumour
40%
Tumor Marker
20%
Vascular Endothelial Growth Factor
20%
Angiogenesis Inhibitor
20%
Necrosis
20%
Pituitary Adenoma
20%
Radiation Therapy
20%